Undergrading and understaging in patients with clinically insignificant prostate cancer who underwent radical prostatectomy

International Braz J Urol

Volumn 36, Issue 3, 2010, Pages 292-299

  Oliveira, Irai S ^a   Pontes Junior, Jose ^a   Abe, Daniel K ^a   Crippa, Alexandre ^a   Dall'Oglio, Marcos F ^a   Nesralah, Adriano J ^a   Leite, Katia R M ^a   Reis, Sabrina T ^a   Srougi, Miguel ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Gleason score; Prostate neoplasms; Prostatectomy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; CANCER INVASION; CANCER STAGING; CHI SQUARE DISTRIBUTION; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; NEEDLE BIOPSY; PATHOLOGY; PROGNOSIS; PROSTATE; PROSTATE TUMOR; PROSTATECTOMY; TUMOR RECURRENCE;

AGED; BIOPSY, NEEDLE; CHI-SQUARE DISTRIBUTION; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 77956131591     PISSN: 16775538     EISSN: 16776119     Source Type: Journal    
DOI: 10.1590/S1677-55382010000300005     Document Type: Article

References (22)

1. Franks LM: Proceedings: Etiology, epidemiology, and pathology of prostatic cancer. Cancer. 1973; 32: 1092-5.
2. Hølund B: Latent prostatic cancer in a consecutive autopsy series. Scand J Urol Nephrol. 1980; 14: 29-35.
3. Canadian Cancer Society/National Cancer Institute of Canada: Canadian Cancer Statistics 2000, Toronto, Canada, 2000.
4. Epstein JI, Walsh PC, Carmichael M, Brendler CB: Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA. 1994; 271: 368-74.
5. Choo R, Klotz L, Danjoux C, Morton GC, DeBoer G, Szumacher E, et al.: Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol. 2002; 167: 1664-9.
6. Stamey TA, McNeal JE, Yemoto CM, Sigal BM, Johnstone IM: Biological determinants of cancer progression in men with prostate cancer. JAMA. 1999; 281: 1395-400.
7. Geary ES, Stamey TA: Pathological characteristics and prognosis of nonpalpable and palpable prostate cancers with a Hybritech prostate specific antigen of 4 to 10 ng./mL. J Urol. 1996; 156: 1056-8.
8. Müntener M, Epstein JI, Hernandez DJ, Gonzalgo ML, Mangold L, Humphreys E, et al.: Prognostic significance of Gleason score discrepancies between needle biopsy and radical prostatectomy. Eur Urol. 2008; 53: 767-75; discussion 775-6.
9. Guimaraes MS, Quintal MM, Meirelles LR, Magna LA, Ferreira U, Billis A: Gleason score as predictor of clinicopathologic findings and biochemical (PSA) progression following radical prostatectomy. Int Braz J Urol. 2008; 34: 23-9.
10. Cohen MS, Hanley RS, Kurteva T, Ruthazer R, Silverman ML, Sorcini A, et al.: Comparing the Gleason prostate biopsy and Gleason prostatectomy grading system: the Lahey Clinic Medical Center experience and an international meta-analysis. Eur Urol. 2008; 54: 371-81.
11. Fine SW, Epstein JI: A contemporary study correlating prostate needle biopsy and radical prostatectomy Gleason score. J Urol. 2008; 179: 1335-8; discussion 1338-9.
12. Nesrallah L, Nesrallah A, Antunes AA, Leite KR, Srougi M: The role of extended prostate biopsy on prostate cancer detection rate: a study performed on the bench. Int Braz J Urol. 2008; 34: 563-70; discussion 570-1.
13. Leite KR, Srougi M, Dall'Oglio MF, Sanudo A, Camara-Lopes LH: Histopathological findings in extended prostate biopsy with PSA < or = 4 ng/mL. Int Braz J Urol. 2008; 34: 283-90; discussion 290-2.
14. Jeldres C, Suardi N, Walz J, Hutterer GC, Ahyai S, Lattouf JB, et al.: Validation of the contemporary epstein criteria for insignificant prostate cancer in European men. Eur Urol. 2008; 54: 1306-13.
15. Chun FK, Suardi N, Capitanio U, Jeldres C, Ahyai S, Graefen M, et al.: Assessment of pathological prostate cancer characteristics in men with favorable biopsy features on predominantly sextant biopsy. Eur Urol. 2009; 55: 617-28-6.
16. D'Amico AV, Wu Y, Chen MH, Nash M, Renshaw AA, Richie JP: Pathologic findings and prostate specific antigen outcome after radical prostatectomy for patients diagnosed on the basis of a single microscopic focus of prostate carcinoma with a gleason score
17. Harnden P, Naylor B, Shelley MD, Clements H, Coles B, Mason MD: The clinical management of patients with a small volume of prostatic cancer on biopsy: what are the risks of progression? A systematic review and meta-analysis. Cancer. 2008; 112: 971-81. Erratum in: Cancer. 2008; 112: 2101.
18. Goto Y, Ohori M, Arakawa A, Kattan MW, Wheeler TM, Scardino PT: Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies. J Urol. 1996; 156: 1059-63.
19. Bastian PJ, Mangold LA, Epstein JI, Partin AW: Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis. Cancer. 2004; 101: 2001-5.
20. Kattan MW, Eastham JA, Wheeler TM, Maru N, Scardino PT, Erbersdobler A, et al.: Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol. 2003; 170: 1792-7.
21. Kattan MW, Shariat SF, Andrews B, Zhu K, Canto E, Matsumoto K, et al.: The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. J Clin Oncol. 2003; 21: 3573-9.
22. Epstein JI, Chan DW, Sokoll LJ, Walsh PC, Cox JL, Rittenhouse H, et al.: Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol. 1998; 160: 2407-11.